TransCode Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-18.55	-17.56	-6.84	-2.34	-0.61
Depreciation & Amortization	0.52	0.1	0.04	0	0
Share-Based Compensation	1.04	0.4	0.19	0.05	0
Other Operating Activities	-1.08	1.31	1.35	1.81	0.1
Operating Cash Flow	-18.07	-15.76	-5.27	-0.49	-0.51
Capital Expenditures	-0.04	-0.1	-0.25	0	0
Investing Cash Flow	-0.04	-0.1	-0.25	0	0
Share Issuance / Repurchase	15.91	0.01	26.38	0	0
Debt Issued / Paid	0	0	0	1.19	0.5
Other Financing Activities	-	-	-0.86	-0.07	-
Financing Cash Flow	15.91	0.01	25.52	1.12	0.5
Net Cash Flow	-2.2	-15.86	20	0.62	-0.01
Free Cash Flow	-18.11	-15.86	-5.52	-0.49	-0.51
Free Cash Flow Per Share	-101.17	-977.90	-523.98	-85.06	-87.75

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).